WCLC 2025 - Posters & ePosters-EP.06.77 Exploring the Impact of Peripheral Immune Landscape on Immunotherapy Outcomes in Non-Small Cell Lung Cancer

EP.06.77 Exploring the Impact of Peripheral Immune Landscape on Immunotherapy Outcomes in Non-Small Cell Lung Cancer

Pdf Summary

This study by Ester Munera Maravilla explores the influence of the peripheral immune landscape on immunotherapy outcomes in patients with non-small cell lung cancer (NSCLC), specifically those with advanced-stage adenocarcinoma and high PD-L1 expression (≥50%). The cohort primarily consisted of smokers and patients treated with anti-PD-1 therapies, with some receiving additional chemotherapy.<br /><br />The urgent need for reliable, non-invasive biomarkers to predict immunotherapy response motivated this research. Peripheral blood immune profiles were analyzed using gene expression approaches, focusing on 770 genes. Principal component analysis revealed no clear clustering based on clinical variables such as sex, smoking status, or disease stage.<br /><br />Using LASSO regression, nine genes (BID, CCL3L1, CCR6, CD84, CXCR5, HLA-DQA1, HLA-DQB1, MS4A2, PTGDR2) were identified as significantly associated with durable clinical benefit at six months. Multivariate Cox regression further confirmed the prognostic value of these genes alongside clinicopathological factors.<br /><br />Risk scores incorporating these genes were developed and shown to predict progression-free survival and overall survival with good sensitivity and specificity, indicating their potential clinical utility. The gene signatures reflect mechanisms involving immune activation and infiltration within the tumor microenvironment, underscoring the role of an active peripheral immune system in favorable immunotherapy outcomes.<br /><br />This study presents a promising peripheral blood gene expression biomarker panel that could aid in predicting which NSCLC patients will benefit from anti-PD-1-based immunotherapy. Further validation is warranted to confirm the clinical applicability of these findings and to enhance personalized treatment strategies in lung cancer immunotherapy.

Asset Subtitle

Ester Munera

Meta Tag

Speaker Ester Munera

Topic Pathology and Biomarkers

Keywords

non-small cell lung cancer

NSCLC

immunotherapy

peripheral immune landscape

PD-L1 expression

anti-PD-1 therapy

gene expression profiling

biomarkers

LASSO regression

progression-free survival